Antibiotic Use and Adverse Events
Antibiotic Use and Adverse Events
批准号:
7275521
负责人:
Sharon B Meropol
金额:
$7.49万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-02-05 至 2010-02-04
关键词:
AcuteAcute respiratory infectionAddressAdverse eventAmbulatory CareAntibiotic TherapyAntibioticsAntimicrobial ResistanceAttentionAttitudeAwardBeliefBenefits and RisksCaringClassClinicalClinical TrialsCohort StudiesComputerized Medical RecordConditionControl GroupsDataDatabasesDevelopmentEnsureEventExposure toFluoroquinolonesFrequenciesFutureGeneral PracticesGuidelinesIndividualIntegration Host FactorsInterventionLearningMacrolidesMarketingMedicalMethodologyMethodsNatural experimentNumbersOffice VisitsOutcomeOutpatientsPatient PreferencesPatientsPharmaceutical PreparationsPhysiciansPopulationPopulation Attributable RisksProspective StudiesProviderPublic HealthRandomized Clinical TrialsRangeRateResearchResearch PersonnelRespiratory Tract InfectionsRiskRisk FactorsSerious Adverse EventSevere Adverse EventTrainingVisitbasebeta-Lactamsdrug efficacyimprovedsuccess
中文摘要
描述(由申请人提供):美国人群抗生素暴露的估计范围从每3年一次到几乎每年两次;几乎一半的美国门诊抗生素使用是不必要的。抗生素过度使用对个人和社会都有影响,包括药物不良事件(ADEs)和不断升级的抗菌素耐药性。在患者-提供者接触层面限制过度使用的努力收效甚微。即使抗生素使用导致的相对较小的个体ADE风险也可能导致较大的人群归因风险。很少有关于抗生素不良反应的研究纳入了没有抗生素暴露的对照组。虽然随机临床试验对于确保暴露组和未暴露组之间的可比性是理想的,但它们并不总是可行的。观察性数据可以为研究抗生素使用的个体后果提供一种有效的方法,但研究需要解决混淆问题,特别是指征混淆。加强调整方法以确保治疗组和对照组之间的可比性,从而帮助我们最佳地利用观察数据。这项回顾性队列研究使用来自英国全科医学研究数据库的观察数据来研究抗生素使用引起的不良反应。本研究利用了急性呼吸道感染(ARIs)的抗生素治疗是可变的这一事实,反映了临床医生的信念、患者的偏好以及潜在的临床和非临床因素。本研究的主要目的是比较因急性呼吸道感染而接受抗生素治疗的患者与未接受抗生素治疗的急性呼吸道感染患者发生严重不良事件的风险。假设是抗生素的使用与不良事件的风险增加有关;任何增加的风险都可以归因于ade。次要目的是比较暴露于不同种类抗生素药物的急性呼吸道感染患者发生严重不良事件的风险,以及比较暴露于抗生素的急性呼吸道感染患者与未暴露于抗生素的患者发生较轻严重不良事件的风险。我们将探索控制患者临床因素(如合并症和就诊频率)混淆的方法。这项研究将支持申请人发展成为一个富有成效的独立研究者。这项研究与公共卫生相关,因为它建议评估抗生素相关ade的个体风险,并改进方法以解决使用观察数据固有的混淆问题。结果将有助于规划一项使用电子病历数据的前瞻性研究,以更有效地将个人风险和益处纳入抗生素处方决策,最大限度地减少抗生素处方的不良后果,并减少不必要的抗生素使用。
英文摘要
DESCRIPTION (provided by applicant): Estimates of antibiotic exposure in the U.S. population range from once every 3 years to almost twice yearly; almost half of U.S. outpatient antibiotic use is unnecessary. Antibiotic overuse has individual and societal consequences, including adverse drug events (ADEs) and escalating antimicrobial resistance. Efforts to limit overuse at the patient-provider encounter level have had limited success. Even relatively small individual ADE risks from antibiotic use could result in large population attributable risks. Few studies on antibiotic ADEs have included a control group of patients without antibiotic exposure. While randomized clinical trials are ideal for ensuring comparability between exposed and unexposed groups, they are not always feasible. Observational data could offer an efficient way to study individual consequences of antibiotic use, but studies need to address confounding issues, especially confounding by indication. Enhanced adjustment methods to ensure comparability between treatment and control groups would thus help us make optimal use of observational data. This retrospective cohort study uses observational data from the UK's General Practice Research Database to study ADEs consequent to antibiotic use. This study takes advantage of the fact that antibiotic treatment for acute respiratory infections (ARIs) is variable, reflecting clinician beliefs, patient preferences and underlying clinical and nonclinical factors. The primary aim is to compare the risk of a severe adverse event between patients prescribed antibiotics, conditional on an office visit for an ARI vs. the risk for patients with ARI office visits not exposed to antibiotics. The hypothesis is that antibiotic use is associated with an increased risk of adverse events; any increased risk can be attributable to ADEs. Secondary aims are to compare the risk of a severe adverse event between patients with ARIs exposed to different classes of antibiotic drugs, and to compare the risk of a less-severe adverse event between patients with ARIs exposed to antibiotics vs. the risk for unexposed patients. We will explore methods to control for confounding by patient clinical factors such as comorbid conditions and visit frequency. This study will support the applicant's development into a productive independent investigator. This study is relevant to public health as it proposes to assess the individual risk of antibiotic-related ADEs and refine methodologies to address confounding issues inherent with using observational data. Results would help plan a prospective study using electronic medical record data to more effectively incorporate individual risks and benefits into antibiotic prescribing decisions, minimize adverse outcomes of antibiotic prescribing, and decrease unnecessary antibiotic use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Infant Antibiotic Resistance and Implications for Therapeutic Decision-making
-
批准号:8383248
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2012
-
负责人:Sharon B Meropol
-
依托单位:
Infant Antibiotic Resistance and Implications for Therapeutic Decision-making
-
批准号:8511560
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2012
-
负责人:Sharon B Meropol
-
依托单位:
Antibiotic Use and Adverse Events
-
批准号:7388883
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2007
-
负责人:Sharon B Meropol
-
依托单位:
Antibiotic Use and Adverse Events
-
批准号:7558487
-
项目类别:
-
资助金额:$7.06万
-
财政年份:2007
-
负责人:Sharon B Meropol
-
依托单位:
海外基金